Prosecution Insights
Last updated: April 19, 2026

Examiner: WESTON, ALYSSA G

Tech Center 1600 • Art Units: 1633 1699

This examiner grants 64% of resolved cases

Performance Statistics

63.9%
Allow Rate
+3.9% vs TC avg
163
Total Applications
+49.4%
Interview Lift
1299
Avg Prosecution Days
Based on 97 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
22.1%
§102 Novelty
38.3%
§103 Obviousness
27.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18382626 CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES Non-Final OA President and Fellows of Harvard College
18658077 METHODS OF TREATING MITOCHONDRIAL DISORDERS Non-Final OA The Regents of the University of California
17440116 AUGMENTATION OF T-CELL ACTIVATION BY OSCILLATORY FORCES AND ENGINEERED ANTIGEN-PRESENTING CELLS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17260222 CHIMERIC ANTIGEN RECEPTOR T CELLS Final Rejection The Regents of the University of California
17047975 COMPOSITIONS AND METHODS FOR CYTOTOXIC CD4+ T CELLS Non-Final OA The Regents of the University of California
18558811 PHARMACEUTICAL COMPOSITION COMPRISING CHORION EXTRACT-DERIVED EXOSOMES AS ACTIVE INGREDIENT FOR PROMOTING OSTEOGENESIS Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18029750 METHODS FOR IDENTIFYING MODULATORS OF NATURAL KILLER CELL INTERACTIONS Final Rejection The Johns Hopkins University
18748469 OSTEOGENIC COMPOSITIONS AND METHODS OF MAKING THE SAME Non-Final OA Alphatec Spine, Inc.
17602277 METHODS AND COMPOSITIONS FOR PROGRAMMING T CELL DIFFERENTIATION AND ENHANCING T CELL PROLIFERATION Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17784935 ENGINEERED IMMUNE CELLS WITH REDUCED TOXICITY AND USES THEREOF Final Rejection The General Hospital Corporation
17760245 CYTOTOXIC T CELLS DERIVED FROM HUMAN T CELL-DERIVED IPS CELLS Non-Final OA THE UNIVERSITY OF TOKYO
17928674 COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS USING CRISPR-BASED BASE EDITOR SYSTEMS Non-Final OA The Trustees of Columbia University in the City of New York
18660178 METHODS FOR THE LONG-TERM EXPANSION OF GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF Non-Final OA UNIVERSITY OF SOUTHERN CALIFORNIA
18276416 GENERATION OF INDUCED PLURIPOTENT STEM CELL LINES FROM HUMAN PATIENTS WITH MUTATIONS IN THE GLUCOKINASE GENE Non-Final OA Qatar Foundation for Education, Science and Community Development
17782600 ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS Final Rejection Fate Therapeutics, Inc.
18116349 METHOD FOR PRODUCING ASTROCYTE-LIKE CELLS Final Rejection KEIO UNIVERSITY
18626460 RECRUITMENT METHODS AND COMPOUNDS, COMPOSITIONS AND SYSTEMS FOR RECRUITMENT Non-Final OA Pairwise Plants Services, Inc.
17759271 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CD83 AND INTERLEUKIN 6 RECEPTOR Final Rejection H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18565425 DUAL-LAYER CULTURE SUBSTRATE Non-Final OA WASEDA UNIVERSITY
18517525 SEPARATION DEVICE AND METHOD FOR SEPARATING TO-BE-SEPARATED MATERIAL USING SAME Non-Final OA NISSAN CHEMICAL CORPORATION
17774088 GENERATION OF CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FROM STEM CELLS AND THERAPEUTIC USES THEREOF Final Rejection City of Hope
18517066 METHOD FOR INDUCING AND DETECTING SOLUBLE LOX-1 (sLOX-1) IN CULTURED BLOOD CLOTS Non-Final OA GEORGE MASON UNIVERSITY
17176422 APPARATUS FOR SEPARATING THE CELLULAR AND LIQUID PORTIONS OF A WHOLE BLOOD SAMPLE Final Rejection UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
18247651 LONG-TERM AND FUNCTIONAL CULTURE OF HEPATIC ORGANOIDS (eHEPO) DERIVED FROM EPCAM+ ENDODERMAL PROGENITOR CELLS DIFFERENTIATED FROM INDUCED PLURIPOTENT STEM CELLS Non-Final OA KOC UNIVERSITESI
17994883 CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF Final Rejection iCell Gene Therapeutics Inc.
18252627 CULTURED ADIPOSE TISSUE Non-Final OA Trustees of Tufts College
17912480 ISCHEMIC HEART DISEASE ANIMAL MODEL USING 3-DIMENSIONAL BIOPRINTED OCCLUDE, AND MANUFACTURING METHOD THEREFOR Final Rejection INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
17915802 Cell Non-Final OA AUTOLUS LIMITED
17915689 METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST Final Rejection AUTOLUS LIMITED
17436673 COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR Non-Final OA AUTOLUS LIMITED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month